Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRDFNASDAQ:CSBRNASDAQ:OTLKNASDAQ:SLDB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$5.75+6.7%$2.81$0.94▼$6.42$240.81M1.724.64 million shs1.77 million shsCSBRChampions Oncology$5.03+0.2%$10.15$7.19▼$14.68$68.24M0.45,767 shs937 shsOTLKOutlook Therapeutics$9.37+7.9%$8.12$4.00▼$40.60$112.95MN/A1.36 million shs1.47 million shsSLDBSolid Biosciences$14.25+5.0%$9.82$1.81▼$14.99$512.36M1.88328,454 shs281,354 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology+6.68%+15.93%+236.26%+296.55%+278.29%CSBRChampions Oncology+0.20%-4.91%-15.46%-7.02%+23.28%OTLKOutlook Therapeutics+7.95%+38.20%+4.58%+9.80%-53.15%SLDBSolid Biosciences+5.01%+7.39%+50.00%+111.74%+258.94%Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology1.1413 of 5 stars3.52.00.00.02.80.00.0CSBRChampions Oncology3.9011 of 5 stars3.33.00.04.50.04.20.0OTLKOutlook Therapeutics3.5006 of 5 stars4.44.00.00.03.80.00.6SLDBSolid Biosciences3.8337 of 5 stars3.54.00.00.03.84.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology3.00Buy$10.5082.61% UpsideCSBRChampions Oncology2.50Moderate Buy$7.5049.11% UpsideOTLKOutlook Therapeutics2.75Moderate Buy$46.43395.46% UpsideSLDBSolid Biosciences3.00Buy$18.2528.07% UpsideCurrent Analyst RatingsLatest SLDB, CRDF, CSBR, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/18/2024SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$8.00 ➝ $21.003/15/2024SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.003/14/2024SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/14/2024SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$8.00 ➝ $20.003/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.003/1/2024CRDFCardiff OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$490K524.31N/AN/A$1.56 per share3.69CSBRChampions Oncology$53.87M1.27N/AN/A($0.15) per share-33.53OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/ASLDBSolid Biosciences$8.09M66.51N/AN/A$6.27 per share2.27Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$41.44M-$0.93N/AN/AN/A-8,492.01%-50.13%-44.31%5/2/2024 (Estimated)CSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)SLDBSolid Biosciences-$96.01M-$4.84N/AN/AN/AN/A-62.11%-48.99%5/9/2024 (Estimated)Latest SLDB, CRDF, CSBR, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023SLDBSolid Biosciences-$1.01-$1.00+$0.01-$1.00N/AN/A2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 million2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A7.417.41CSBRChampions OncologyN/A0.600.60OTLKOutlook TherapeuticsN/A0.440.44SLDBSolid Biosciences0.018.948.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%CSBRChampions Oncology41.30%OTLKOutlook Therapeutics11.20%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology6.30%CSBRChampions Oncology45.69%OTLKOutlook Therapeutics5.30%SLDBSolid Biosciences19.33%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology3144.68 million41.86 millionOptionableCSBRChampions Oncology14313.59 million7.38 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionNot OptionableSLDBSolid Biosciences8837.76 million30.46 millionOptionableSLDB, CRDF, CSBR, and OTLK HeadlinesSourceHeadlineSolid Biosciences (NASDAQ:SLDB) Reaches New 1-Year High at $14.99marketbeat.com - March 27 at 4:20 PMSolid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposiumfinance.yahoo.com - March 27 at 10:24 AMSLDB Apr 2024 7.500 putfinance.yahoo.com - March 24 at 7:35 PMCautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciencesmarkets.businessinsider.com - March 19 at 7:14 AMSolid Biosciences (NASDAQ:SLDB) Given New $21.00 Price Target at Barclaysamericanbankingnews.com - March 19 at 4:54 AMBarclays Increases Solid Biosciences (NASDAQ:SLDB) Price Target to $21.00marketbeat.com - March 18 at 5:32 PMSolid Biosciences (NASDAQ:SLDB) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 18 at 4:34 PMSolid Biosciences (SLDB) Gets a Buy from Barclaysmarkets.businessinsider.com - March 18 at 9:36 AMSolid Biosciences Inc. Expected to Post FY2027 Earnings of ($2.33) Per Share (NASDAQ:SLDB)americanbankingnews.com - March 18 at 2:44 AMSLDB Sep 2024 17.500 callfinance.yahoo.com - March 16 at 9:18 AMSolid Biosciences (NASDAQ:SLDB) Receives New Coverage from Analysts at Citigroupmarketbeat.com - March 15 at 8:17 AMBuy Rating Affirmed for Solid Biosciences on Promising Pipeline and Financial Stabilitymarkets.businessinsider.com - March 14 at 12:30 PMSolid Biosciences (NASDAQ:SLDB) Upgraded to Overweight at Piper Sandlermarketbeat.com - March 14 at 8:38 AMSolid Biosciences Inc.: Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Resultsfinanznachrichten.de - March 13 at 3:36 PMSolid Biosciences Stock Drops 4% Due To Wider Loss In Q4markets.businessinsider.com - March 13 at 3:36 PMSolid Biosciences, Cue Biopharma, Annexon among healthcare moversmsn.com - March 13 at 10:36 AMSolid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Resultsglobenewswire.com - March 13 at 7:44 AMSolid Biosciences price target raised by $7 at H.C. Wainwright, here's whyrealmoney.thestreet.com - March 11 at 12:25 PMLeerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB)markets.businessinsider.com - March 11 at 7:24 AMSolid Biosciences enters licensing deal with Armatus Biothepharmaletter.com - March 7 at 4:00 PMSolid Biosciences signs agreement with Armatus Bio for AAV-SLB101msn.com - March 7 at 10:59 AMSolid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDfinance.yahoo.com - March 7 at 10:59 AMSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest Updatemarketbeat.com - March 1 at 10:54 PMSolid Biosciences Stock (NASDAQ:SLDB) Insider Tradesbenzinga.com - February 22 at 5:24 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Champions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Solid BiosciencesNASDAQ:SLDBSolid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.